UMIN ID: UMIN000055395
Registered date:02/09/2024
Epidemiological study of second-line treated non-small cell lung cancer (NSCLC) with HER2 mutation in Japan
Basic Information
| Recruitment status | Complete: follow-up continuing |
|---|---|
| Health condition(s) or Problem(s) studied | non-small cell lung cancer (NSCLC) |
| Date of first enrollment | 2024/06/18 |
| Target sample size | 2700 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Patient information at registration to C-CAT database 1. Patient characteristics 2. Clinical characteristics 3. Genetic alterations |
|---|---|
| Secondary Outcome | 1. Second-line lung cancer treatment types 2. Overall response rate (ORR) 3. Disease control rate (DCR) 4. Time on treatment (ToT) 5. Overall survival (OS) 6. Reasons for the second-line lung cancer treatment termination |
Key inclusion & exclusion criteria
| Age minimum | 18years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | None. |
Related Information
| Primary Sponsor | Nippon Boehringer Ingelheim Co., Ltd. |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Nippon Boehringer Ingelheim Co., Ltd. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Hana Kimura |
| Address | 2-1-1 Osaki, Shinagawa-ku, Tokyo Japan 141-6017 |
| Telephone | 070-2674-6485 |
| hana.kimura@boehringer-ingelheim.com | |
| Affiliation | Nippon Boehringer Ingelheim Co., Ltd Medicine Division Real World Evidence Japan |
| scientific contact | |
| Name | Hana Kimura |
| Address | 2-1-1 Osaki, Shinagawa-ku, Tokyo Japan |
| Telephone | 070-2674-6485 |
| hana.kimura@boehringer-ingelheim.com | |
| Affiliation | Nippon Boehringer Ingelheim Co., Ltd Medicine Division Real World Evidence Japan |